Immune effector cells in idiopathic pulmonary fibrosis

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 5, 1997, Pages 348-355

  Agostini, Carlo ^a   Siviero, Marta ^a   Semenzato, Gianpietro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

HUMAN; IMMUNOLOGY; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; NEUTROPHIL; REVIEW; TH1 CELL; TH2 CELL;

CYTOKINES; HUMANS; LUNG; MACROPHAGES, ALVEOLAR; NEUTROPHILS; PULMONARY FIBROSIS; TH1 CELLS; TH2 CELLS;

EID: 0031225882     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199709000-00006     Document Type: Article

References (57)

1. Crouch E: Pathology of pulmonary fibrosis. Am J Physiol 1990, 259:L159-L184.
2. King TH, Shaw R: Cryptogenic fibrosing alveolitis and cryptogenic organizing pneumonia. In Immunology and Management of Interstitial Lung Diseases. Edited by Walters EH, du Bois RM. London: Chapman & Hall; 1995:61-94.
3. Agostini C, Semenzato C: Immunology of idiopathic pulmonary fibrosis. Curr Opin Pulm Med 1996, 2:364-368. A 1996 overview that covers recent immunologic aspects of idiopathic pulmonary fibrosis.
4. Lohmann-Matthes ML, Steinmuller C, Franke-Ullmann G: Pulmonary immune cells in health and disease: pulmonary macrophages. Eur Respir J 1994, 7:1678-1689.
5. Thompson AB, Robbins RA, Romberger DJ: Immunological functions of the pulmonary epithelium. Eur Respir J 1995, 8:127-149.
6. Chen BDM, Mueller M, Chou TH: Role of GM-CSF in the regulation of alveolar macrophage proliferation and differentiation. J Immunol 1988, 141:139-144.
7. Xing Z, Tremblay GM, Sime JS, Gauldie J: Overexpression of granulocyte-macrophage colony stimulating factor induces pulmonary granulation tissue formation and fibrosis by induction of transforming growth factor-β1 and myofibroblast accumulation. Am J Pathol 1997, 150:59-66. GM-CSF plays a direct role in pulmonary fibrogenesis through its ability to induce TGF-β1 in macrophages and the subsequent emergence of myofibroblast phenotype.
8. Campbell DA, Poulter LW, du Bois RM: Phenotypic analysis of alveolar macrophages in normal subjects and in patients with interstitial lung disease. Thorax 1986, 41:429-434.
9. Noble B, du Bois RM, Poulter LW: The distribution of phenotypically distinct macrophage subsets in the lung of patients with cryptogenic fibrosing alveolitis. Clin Exp Immunol 1989, 76:41-46.
10. Pantelidis P, Southcott AM, Black CM, du Bois RM: Up-regulatlon of IL-8 secretion by alveolar macrophages from patients with fibrosing alveolitis: a subpopulation analysis. Clin Exp Immunol 1997, 108:95-104. There is an increased number of IL-8 secreting-alveolar macrophages in the lungs of patients with IPF. There is an association between the expression of RFD7 markers and IL-8 expression by alveolar macrophages.
11. Zhang K, Phan SH: Cytokines and pulmonary fibrosis. Biol Signals 1996, 5:232-239. A review illustrating the role of a variety of cytokines in the pathophysiology of pulmonary fibrosis.
12. 2. J Biol Chem 1993, 268:10364-10371.
13. Shanley TP, Warner RL, Ward PA: The role of cytokines and adhesion molecules in the development of inflammatory injury. Mol Med Today 1995, 1:40-45.
14. Moller DR, Forman JD, Liu MC: Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996, 156:4952-4960.
15. Kunkel SL, Lukacs NW, Strieter RM, Chensue SW: TH1 and TH2 responses regulate experimental lung granuloma development. Sarcoidosis, Vasc Dif Lung Dis 1996, 13:120-128. This excellent review describes the Th1/Th2 paradigm in the context of granuloma and fibrosis development in the lung. Required reading.
16. Agostini C, Trentin L, Facco M, Sancetta R, Cerutti A, Tassinari C, Cimarosto L, Adami F, Cipriani A, Zambello R, Semenzato G: Role of IL-15, IL-2 and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol 1996, 7:910-918. IL-15 is involved in local development of T cell alveolitis in a potentially fibrosing interstitial lung disorder.
17. Prior C, Haslam P: In vivo levels and in vitro production of interferon gamma in fibrosing interstitial lung diseases. Clin Exp Immunol 1992, 88:280-287.
18. Khalil N, O'Connor RN, Flanders KC, Unruh H: TGF-β1, but not TGF-β2 or TGF-β3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am J Respir Cell Mol Biol 1996, 14:131-138. This study demonstrates that although TGF-β2 and TGF-β3 are ubiquitously expressed in the lung, TGF-β1 is expressed in epithelial cells of fibrotic lungs in which the presence of TGF-β1 is not disease-specific but is an indication of the chronicity of the injury.
19. Mariani T, Roby DJ, Mecham RP, Parks WC, Crouch E, Pierce RA: Localization of type I procollagen gene expression in silica-induced granulomatous lung disease and implication of transforming growth factor-β as a mediator of fibrosis. Am J Pathol 1996, 148:151-164.
20. Korfhagen TR, Swantz RJ, Wert SE, McCarty JM, Kerlakian CB, Glasser SW, Whitsett JA: Respiratory epithelial expression of human transforming growth factor-α induces lung fibrosis in transgenic mice. J Clin Invest 1994, 93:1691-1699.
21. Premsck BE, Schall TJ: Chemokine receptors: gateways to inflammation and infection. Nature Med 1996, 2:1174-1178. A brief but well-written review on the role of an emerging family of cytokines in inflammation and infection.
22. Smith RE: Chemotactic cytokines mediate leukocyte recruitment in fibrotic lung disease. Biol Signals 1996, 5:223-231. The author's experiments strongly support the hypothesis that chemokines contribute to the recruitment of leukocytes during the inflammatory processes modulating pulmonary fibrosis.
23. Antoniades HN, Neville-Golden T, Galanopoulos T, Kradin R, Valente AJ, Graves DT: Expression of monocyte chemoattractant protein-1 mRNA in human idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 1992, 89:5371-5375.
24. Zhang K, Gharaee-Kermani M, Jones ML, Warren JS, Phan SH: Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. J Immunol 1994, 153:4733-4741.
25. Nakamura H, Fujishima S, Waki Y, Urano T, Sayama K, Terashima T, Soejima K, Sakamaki F, Tasaka S, Ishizaka A, Kawashiro T, Kanazawa M: Priming of alveolar macrophages for interleukin-8 production in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995, 152:1579-1586.
26. Taub DD, Anver M, Oppenheim JJ: T lymphocyte recruitment by interleukin-8 (IL-8): IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest 1996, 97:1931-1941. A novel effect of IL-8: It induces neutrophil degranulation, favoring the recruitment of T cells.
27. Zhang K, Gharaee-Kermani M, McGary B, Remick D, Phan SM: TNF-α mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J Immunol 1996, 158:954-959. These findings suggest a novel mechanism through which TNF-α could mediate pulmonary fibrosis.
28. Gharaee-Kermani M, Phan SM: Lung interleukin-5 in murine bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 1997, 16:438-447. IL-5 is upregulated in the murine model and favors eosinophil recruitment and activation at sites of fibrosis development.
29. Mauviel A, Daireaux M, Redini F, Galera P, Loyau G, Pujol JP: Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblasts. FEBS Lett 1988, 236:47-50.
30. Homma S, Nagaoka I, Abe H, Takahashi K, Seyama K, Nukiva T, Kira S: Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am J Respir Crit Care Med 1995, 152:2084-2089.
31. Nagaoka I, Trapnell BC, Crystal RG: Up-regulation of platelet-derived growth factor-A and -B gene in individuals with idiopathic pulmonary fibrosis. J Clin Invest 1990, 85:2023-2027.
32. Aston C, Jagirdar J, Lee TC, Hur T, Hintz RL, Rom WN: Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995, 151:1597-1603.
33. Wilborn J, Bailie M, Coffey M, Burdich M, Stieter R, Peters-Golden M: Constitutive activation of the 5-lypoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996, 97:1827-1836. The authors document the constitutive activation of the 5-lypoxygenase pathway in the lung of patients with IPF.
34. Lynch JP III, Standiford TJ, Rolfe MW, Kunkel SL, Strieter RM: Neutrophilic alveolitis in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1992, 145:1433-1439.
35. Cantin AM, North SL, Fells GA, Hubbard RC, Crystal RG: Oxidant mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987, 79:1665-1673.
36. Gadeck JE, Kelman JA, Fells GA, Weiberger SE, Horwitz AL: Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis. N Engl J Med 1979, 301:737-742.
37. Lenz AG, Costabel U, Maier KL: Oxidized BAL fluid protein in patients with interstitial lung diseases. Eur Respir J 1996, 9:307-312. Oxidative reactions are involved in the pathophysiology of lung damage.
38. King TE, Shaw R: Cryptogenic fibrosing alveolitis and cryptogenic organizing pneumonia. In Immunology and Management of Interstitial Lung Diseases. Edited by Walter EH, du Bois RM. London: Chapman & Hall Medical; 1995:61-94.
39. Cassatella MA: The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995, 16:21-26.
40. Jordana M: Mast cells and fibrosis: who's on first? Am J Respir Cell Mol Biol 1993, 8:7-8.
41. Inoue Y, King TE Jr, Tinkle SS, Dockstader K, Newman LS: Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am J Pathol 1996, 149:2037-2054. Basic fibroblast growth factor-producing cells in the lung interstitium are mast cells. They are most abundant in idiopathic pulmonary fibrosis. BFGF concentrations in bronchoalveolar lavage fluid correlate with bronchoalveolar lavage cellularity and severity of gas exchange abnormalities.
42. Agostini C, Trentin L, Zambello R, Semenzato G: Pulmonary alveolar macrophages in patients with sarcoidosis and hypersensitivity pneumonitis: characterization by monoclonal antibodies. J Clin Immunol 1986, 7:64-70.
43. Hancock WW, Muller WA, Cotran RS: Interleukin-2 receptors are expressed by alveolar macrophages during pulmonary sarcoidosis and are inducible by lymphokine treatment of normal lung macrophages, blood monocytes, and monocyte cell lines. J Immunol 1987, 138:185-191.
44. Gruss HJ, Scott C, Rollins BJ, Brach MA, Herrmann F: Human fibroblasts express functional IL-2 receptors formed by the IL-2R α- and β-chain subunits: association of IL-2 binding with secretion of monocyte chemoattractant protein-1. J Immunol 1996, 157:851-857. IL-2 may serve to integrate fibroblast and monocytes into a coordinated response of the connective tissue initiated by T cells.
45. Yang JP, Renzi PM: Interleukin-2 and lymphocyte-induced eosinophil proliferation and survival in asthmatic patients. J Allerg Clin Immunol 1993, 91:792-799.
46. Aoki Y, Qiu D, Uyei A, Kao PN: Human airway epithelial cells express interleukin 2 in vitro. Am J Physiol 1997, 272:L276-L286. The first report that epithelial cells constitutively produce IL-2 mRNA and protein.
47. Wallace WA, Ramage EA, Lamb D, Howie SE: A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol 1995, 101:436-441.
48. Peterson MW, Monick M, Hunninghake GW: Prognostic role of eosinophils in pulmonary fibrosis. Chest 1987, 92:51-59.
49. Allen JN, Davis WB, Pacht ER: Diagnostic significance of increased bronchoalveolar lavage fluid eosinophils. Am Rev Respir Dis 1990, 142:642-650.
50. Mosmann T: Interleukin-10. In The Cytokine Handbook. Edited by Thompson A. London: Academic Press; 1994:223-237.
51. Zissel G, Homolka J, Schlaak J, Schlaak M, Muller-Quernheim J: Antiinflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 1996, 154:713-719.
52. Armstrong L, Hancock AL, Foley N, Rankin E, Millar AB: Production of interleukin 13 by alveolar macrophages from healthy subjects and patients with fibrotic lung disease. Am J Respir Crit Care Med 1997, 155:A762.
53. Center DM, Kornfeld H, Cruiskshank WW: Interleukin-16 and its function as CD4 ligand. Immunol Today 1996, 17:476-481.
54. Yao Z, Painter SL, Fanslow WC, Dawn U, Macduff BM, Spriggs MK, Armitage RJ: Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155:5483-5486.
55. Lynch JP, McCune WJ: Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997, 155:395-420. This well-written review is required reading because it covers virtually all aspects of immunosuppressive and cytotoxic pharmacotherapy in pulmonary disorders.
56. Hunninghake GW, Kalica AR: Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995, 151:915-918.
57. Coker RK, Laurent GJ: Anticytokine approaches in pulmonary fibrosis: bringing factors into focus. Thorax 1997, 52:294-296. This interesting review suggests that there are compelling reasons to explore anticytokine therapy in pulmonary fibrosis.